Shots: Accent to receive $55M upfront and $1.1B as co-development option and milestone payment, plus royalties and profit split based on the option to co-develop and co-commercialize RMP-targeting therapies for the treatment of cancer in the US Accent will be responsible for research and development activities for a nominated preclinical program through to the end […]Read More
Shots: AbbVie to get an exclusive global license to develop and commercialize JAB-3068 and JAB-3312 from Jacobio AbbVie will provide undisclosed R&D cost to Jacobio for conducting early global CTs of JAB-3068 and JAB-3312. In addition, Jacobio has an exclusive option before registration trial initiation to develop and commercialize the SHP2 program in mainland China, […]Read More
Shots: Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical, development and commercial milestones along with royalties on sales of commercialized products resulting from the collaboration Vividion will be responsible for early drug discovery and pre-clinical development for selected programs and has the right to conduct clinical development up […]Read More
Shots: Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology Recursion will utilize its automated drug discovery platform to discover the potential of TAK-733 by testing 200+ potential molecules from Takeda’s library against cancers carrying mutations TAK-733 is identified as […]Read More
Shots: :stohththShots: The companies intend to establish manufacturing suites at Lonza’s facilities in the US and Switzerland to manufacture mRNA-1273 at both sites. The collaboration will deploy Lonza’s global expertise in technology transfer and manufacturing while the technology transfer expected to begin in Jun’2020 The focus of the collaboration is to enable the manufacturing of […]Read More
Shots: The collaboration will bring Oxford’s recombinant adenovirus vaccine, ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the development and WW manufacturing and distribution of the vaccine The alliance will combine Oxford’s expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities to combat the pandemic ChAdOx1 is based […]Read More
Shots: Fate to receive $50M up front and $50M equity investment at $31/ share and funding for the research and development of collaboration candidates through IND filing. The company will receive up to $1.8B as development & regulatory milestones and up to $1.2B as a commercial milestone along with royalties on global sales of products […]Read More
Shots: Sitryx to receive $50M upfront, $10M equity investment, ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies, including Sitryx’s two lead projects The companies will collaborate for 5yrs. supporting the development of therapies with Sitryx to be […]Read More
Shots: Elevar to receive $20M up front, ~$678M as milestones based on the company’s achievement regarding the product along with royalties on sales of Apealea globally excluding Nordics, Russia, and certain countries in Eastern Europe The agreement allows Elevar the right to sub-license Apealea to other partners in the EU. Elevar will be responsible for […]Read More
Shots: Sangamo to receive $350 million upfront, including $125M license fee & $225M equity investment in Sangamo’s stock or ~24M shares at $9.21/share and is eligible to receive $2.37B as milestones along with royalties on sales of the therapies Biogen to get an exclusive WW right of ST-501 for tauopathies including AD, ST-502 for synucleinopathies […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
